Medication info
Dapagluem Sustained Release Tablet 10/1000 mg (Dapagliflozin Propanediol Monohydrate, Metformin Hydrochloride)

Dapagluem Sustained Release Tablet 10/1000 mg (Dapagliflozin Propanediol Monohydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Ilhwa Co., Ltd.
Appearance
Yellow, double-sided convex oval sustained-release film-coated tablets
Packaging
30 tablets/box [(10 tablets/PTP (Alu-Alu) x 3)]
Approval status
Active

MFDS item code 202300433 · Approved 2023.01.31 · Insurance code 640904470

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse effects of metformin. In patients receiving treatment with metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin previously taken or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. In patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Since this may cause changes in glycemic control, any change in treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, and without other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Use in Elderly Patients).

Ingredients

Manufacturer
Ilhwa Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used to assist in blood sugar control in adult patients with type 2 diabetes by combining dapagliflozin and metformin. It is administered as an adjunct to dietary and exercise therapy for effective blood sugar management. Furthermore, in type 2 diabetes patients who have insufficient blood sugar control with additional cardiovascular disease or risk factors, the effects of dapagliflozin on the occurrence of cardiovascular events should be referenced from a specialist. Therefore, this medication aids in blood sugar control and improves cardiovascular health in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be adjusted gradually to reduce gastrointestinal adverse effects of metformin. In patients receiving treatment with metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the dose of metformin previously taken or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. In patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Since this may cause changes in glycemic control, any change in treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, and without other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Use in Elderly Patients).

Precautions

This medication helps lower blood sugar. However, it should not be used in patients with poor kidney function or conditions such as dehydration, severe infections, or cardiovascular problems. Women who are pregnant or breastfeeding should also refrain from taking this medication. It can occasionally cause a severe condition called lactic acidosis, so any symptoms must be reported to a doctor immediately. There is a risk of hypoglycemia, so caution is required when used with insulin or other hypoglycemic agents. During treatment, urinary tract infections or genital infections may occur, and any related symptoms should be treated immediately. For patients at risk of decreased blood volume or hypotension, blood pressure and kidney function should be monitored frequently. Vitamin B12 levels may decrease, so blood tests may be necessary during long-term treatment. Excessive alcohol consumption can increase risks, so caution is necessary. This medication should be discontinued for a certain period before and after surgery or radiographic procedures, and it should be restarted only after confirming normal kidney function. Elderly patients commonly experience decreased kidney function, so dosing adjustment and regular kidney function tests may be needed. In case of overdose, immediate medical attention is required. This medication has not been established as safe and effective for children.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • reduced fluid volume
  • thirst
Show 85 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • lumbago
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • elevated hematocrit
  • reduced renal creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • reduced vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant neoplasm of the lung
  • uterine leiomyoma
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • dental pain
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periartritis
  • tendinosis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius to preserve its effectiveness.

Appearance and packaging

Appearance

Yellow, double-sided convex oval sustained-release film-coated tablets

Package unit

30 tablets/box [(10 tablets/PTP (Alu-Alu) x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.